J2KBIO Co., Ltd. (KOSDAQ:420570)
South Korea · Delayed Price · Currency is KRW 7,490.00
+290.00 (4.03%)
At close: Jun 29, 2026
J2KBIO Revenue
J2KBIO had revenue of 11.13B KRW in the quarter ending March 31, 2026, with 53.08% growth. This brings the company's revenue in the last twelve months to 36.82B, up 13.00% year-over-year. In the year 2025, J2KBIO had annual revenue of 32.97B, down -0.49%.
Revenue (ttm)
36.82B
Revenue Growth
+13.00%
P/S Ratio
1.19
Revenue / Employee
681.93M
Employees
54
Market Cap
43.80B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 32.97B | -162.83M | -0.49% |
| Dec 31, 2024 | 33.13B | 4.66B | 16.36% |
| Dec 31, 2023 | 28.47B | 12.44B | 77.60% |
| Dec 31, 2022 | 16.03B | 1.81B | 12.75% |
| Dec 31, 2021 | 14.22B | 360.95M | 2.60% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Psomagen | 60.70B |
| Eutilex.Co.,Ltd | 9.51B |
| TegoScience | 5.83B |
| HLB Pep | 5.52B |
| EyeGene | 4.02B |
| Quratis | 1.26B |
| Kainos Medicine | 1.17B |
| Aptamer Sciences | 1.08B |